This invention discloses (20S)-23,23-difluoro-2-methylene-19-norbishomopregnacalciferol-vitaminD analogs, and specifically (20S)-23,23-difluoro-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical usestherefor. This compound exhibits pronounced activity in arresting theproliferation ofundifferentiated cells and inducing their differentiation to the monocyte thusevidencing use as an anti-cancer agent and for the treatment of skin diseasessuch aspsoriasis as well as skin conditions such as wrinkles, slack skin, dry skinandinsufficient sebum secretion. This compound also has little, if any, calcemicactivityand therefore may be used to treat autoimmune disorders or inflammatorydiseases inhumans as well as renal osteodystrophy. This compound may also be used for thetreatment or prevention of obesity.(see above formula)
展开▼
